CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis – from bench to bedside?
by Karla Lam
24th February 2015 •
comment
Submit an article
We welcome contributions from members. Please submit an article for review by our editorial team.
Upload nowCategories
- ACT Consortium (4)
- Adolescent Health (2)
- Child Health (3)
- Clinical Trial Laboratories (53)
- Clinical trials (9)
- Community Engagement (7)
- Coronavirus (1)
- COVID-19 (WEPHREN Resources) (1)
- Data Management and Statistics (4)
- Disease-specific Guidance (47)
- E-Learning (1)
- Ethics and HIV (4)
- Ethics and Informed Consent (3)
- Evidence Based Systematic Reviews (1)
- Funding (1)
- Global Health Research Ethics (10)
- Health Inequality (9)
- Health Policy and Management (10)
- Infectious diseases (50)
- Latest Publications (20)
- Malaria (2)
- Maternal/Fetal health during pregnancy (3)
- Maternal Health (3)
- Microbiology (71)
- Neonatal Health (4)
- Operational/Governance (6)
- Pandemic preparedness (9)
- Postnatal Care (1)
- Publications (14)
- Regulations and Guidelines (16)
- Reports (4)
- Resources (58)
- Results (1)
- Sampling (1)
- SOP (3)
- SOPs (3)
- Test Evaluations (18)
- Tests (44)
- Training (42)
- Training Toolkit (3)
- Trial Design (11)
- Trial Management (14)
- Trial Operations (13)
- Vacccine Production (1)
- Webinar (6)